A
A

Amgen


財經新聞

Cigna expects revenue gains from launches of Humira biosimilars

UPDATE 2-Cigna expects revenue gains from launches of Humira biosimilars Rewrites, adds management and analyst comments, updates shares By Leroy Leo Feb 3 (Reuters) - Cigna Corp CI.N expects its pharmacy benefit management unit to earn more from the second half of 2023 as makers of cheaper versions of AbbVie Inc's ABBV.N arthritis drug Humira will boost aftermarket discounts to gain access to patients.
A
C

Amgen's Tezspire gets FDA Approval For Self-Administration For Patients With Severe Asthma

BRIEF-Amgen's Tezspire gets FDA Approval For Self-Administration For Patients With Severe Asthma Feb 2 (Reuters) - Amgen Inc AMGN.O : AMGEN - ANNOUNCED FDA APPROVED TEZSPIRE FOR SELF-ADMINISTRATION IN PRE-FILLED, SINGLE-USE PEN FOR PATIENTS AGED 12 YEARS & OLDER WITH SEVERE ASTHMA AMGEN INC - FDA HAS APPROVED TEZSPIRE FOR SELF-ADMINISTRATION IN U.S
A
A

AbbVie's Humira gets a U.S. rival, but costs could stay high

FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high Updates to clarify lower price may not be widely used, rather than widely available, and why By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited.
A
C

Wall St falls as Fed decision looms; AMD boosts chipmakers

US STOCKS-Wall St falls as Fed decision looms; AMD boosts chipmakers For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Fed's rate decision expected at 1400 ET AMD expects strong second half of 2023 Amgen weighs on Dow as Q4 revenue falls slightly EA cuts bookings view, shares slide Indexes down: Dow 1.12%, S&P 0.63%, Nasdaq 0.44% Adds comments, details; updates prices By Johann M Cherian and Shreyashi Sanyal Feb 1 (Reuters) - U.S.
A
F
A
E
U
U

U.S. STOCKS Synchrony Financial, Moody's Corp, Funko, Mondelez

BUZZ-U.S. STOCKS ON THE MOVE-Synchrony Financial, Moody's Corp, Funko, Mondelez Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes fell on Wednesday ahead of the Federal Reserve's decision on interest rates later in the day, while an upbeat outlook from Advanced Micro Devices lifted chipmakers.
A
A
B
C
C
M
M
T
A
W
E
J
U
U
S
T
W
R

Wall St dips as Fed decision looms; AMD boosts chipmakers

US STOCKS-Wall St dips as Fed decision looms; AMD boosts chipmakers For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Fed's rate decision expected at 1400 ET AMD expects strong second half of 2023 Amgen weighs on Dow as Q4 revenue falls slightly EA cuts bookings view, shares slide Indexes down: Dow 0.64%, S&P 0.26%, Nasdaq 0.15% Updates prices to open, adds details By Johann M Cherian and Shreyashi Sanyal Feb 1 (Reuters) - U.S.
A
F
A
E
U
U

U.S. STOCKS Tesla, Peloton, Thermo Fisher Scientific

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Peloton, Thermo Fisher Scientific Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes were set to open lower on Wednesday as investors cautiously awaited the Federal Reserve's decision on interest rates later in the day, while chipmaker Advanced Micro Devices climbed on an upbeat outlook.
A
A
B
C
C
D
M
M
T
A
W
E
T
U
S
T

Wall St set to open lower ahead of Fed decision; AMD rises on outlook

US STOCKS-Wall St set to open lower ahead of Fed decision; AMD rises on outlook For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Fed's rate decision expected at 1400 ET AMD expects strong second half of 2023 Amgen slips as Q4 revenue falls slightly EA cuts bookings view, shares slide Social media stocks slip on Snap's warnings Futures off: Dow 0.40%, S&P 0.24%, Nasdaq 0.07% Updates prices, adds comments, details By Johann M Cherian and S
A
F
G
I
A
E
U
U
U

Futures dip on jitters ahead of ADP report, Fed decision

US STOCKS-Futures dip on jitters ahead of ADP report, Fed decision For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Fed's rate decision expected at 1400 ET AMD expects strong second half of 2023 Amgen slips as Q4 revenue falls slightly EA cuts bookings view, shares slide Platform providers slip on Snap's warnings Futures: Dow down 0.36%, S&P off 0.18%, Nasdaq flat By Johann M Cherian Feb 1 (Reuters) - U.S.
A
F
G
I
A
E
U
U
U

Beigene Will Retain Anthony C. Hooper

BRIEF-Beigene Will Retain Anthony C. Hooper Jan 31 (Reuters) - Beigene Ltd 6160.HK : BEIGENE - ON JAN 30, AMGEN ELECTED TO RELINQUISH ITS RIGHT TO APPOINT A DESIGNATED DIRECTOR TO COMPANY'S BOARD OF DIRECTORS BEIGENE - CO WILL RETAIN ANTHONY C. HOOPER Further company coverage: 6160.HK
A

Amgen revenue falls slightly as Lilly COVID deal contributes less

UPDATE 1-Amgen revenue falls slightly as Lilly COVID deal contributes less Adds FTC information request, share move By Sriparna Roy and Michael Erman Jan 31 (Reuters) - Amgen Inc AMGN.O on Tuesday said its fourth-quarter revenue fell slightly as a 4% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly and Co.
A

Amgen - QTRLY Earnings Per Share $3.00; QTRLY Adjusted Earnings Per Share $4.09

BRIEF-Amgen - QTRLY Earnings Per Share $3.00; QTRLY Adjusted Earnings Per Share $4.09 Jan 31 (Reuters) - Amgen Inc AMGN.O : AMGEN - QTRLY TOTAL PRODUCT SALES UP 4% AMGEN - QTRLY EARNINGS PER SHARE $3.00; QTRLY ADJUSTED EARNINGS PER SHARE $4.09 AMGEN INC Q4 EARNINGS PER SHARE VIEW $4.10, REVENUE VIEW $6.77 BILLION -- REFINITIV IBES DATA AMGEN - QTRL
A

Amgen revenue falls slightly as Lilly COVID deal contributes less

Amgen revenue falls slightly as Lilly COVID deal contributes less Jan 31 (Reuters) - Amgen Inc AMGN.O on Tuesday said its fourth-quarter revenue fell slightly as a 4% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly and Co. LLY.N Amgen reported revenue of $6.84 billion in the quarter, down from $6.85 billion a year ago, but ahead of analysts' estimates of $6.77 billion, according to Refinitiv data.
A

Amgen launches biosimilar version of AbbVie's Humira

UPDATE 1-Amgen launches biosimilar version of AbbVie's Humira Adds analysts quote By Khushi Mandowara Jan 31 (Reuters) - Amgen Inc AMGN.O said on Tuesday it launched a biosimilar version of AbbVie Inc's ABBV.N big selling arthritis treatment, the first such competition for Humira in the United States. Amgen said i ts drug, Amjevita, or adalimumab-atto, will have two list prices -- $3,288 and $1,557 per 40 milligram pen device for a two-week supply -- representi ng a discount of 5% a nd 55% to Hu
A

AbbVie's Humira gets a U.S. rival, but costs could stay high

FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high Updates with new CVS policy By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20-year-old drug, with two tiers of pricing.
A
C

Amgen Says Amjevita (Adalimumab-Atto), A Biosimilar To Humira (Adalimumab), Is Now Available In U.S.

BRIEF-Amgen Says Amjevita (Adalimumab-Atto), A Biosimilar To Humira (Adalimumab), Is Now Available In U.S. Jan 31 (Reuters) - Amgen Inc AMGN.O : AMGEN - AMJEVITA (ADALIMUMAB-ATTO), A BIOSIMILAR TO HUMIRA (ADALIMUMAB), IS NOW AVAILABLE IN U.S. AMGEN - AMJEVITA IS ALSO AVAILABLE AT LIST PRICE 5% BELOW CURRENT HUMIRA LIST PRICE AMGEN - AMJEVITA (40 MG
A

AbbVie's Humira gets a U.S. rival, but costs could stay high

FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20-year-old drug, with two tiers of pricing.
A
C

Amgen launches biosimilar version of AbbVie's Humira

Amgen launches biosimilar version of AbbVie's Humira NEW YORK, Jan 31 (Reuters) - Amgen Inc AMGN.O on Tuesday said it was launching Amjevita, or adalimumab-atto, a biosimilar version of AbbVie Inc's ABBV.N big selling arthritis treatment Humira, the first such biosimilar competition for the drug in the United States. Amgen said the drug will have two list prices that represent a discount of either 5% or 55% to Humira, depending on who is doing the purchasing.
A

'Soft landing' or 'no landing'?

MORNING BID-'Soft landing' or 'no landing'? A look at the day ahead in U.S. and global markets from Mike Dolan There's an uncomfortable feeling in markets this week that good news may be bad news once again - mainly because of what the former means for this week's big central banking set pieces. As U.S. Federal Reserve's Federal Open Market Committee kicks off its two-day policymaking meeting, the economic news from around the world brightened considerably.
A
A
A
G
M
P
U
U
A
W
E
J
U
U
S
S
A
P

Amgen Announces Organizational Changes

BRIEF-Amgen Announces Organizational Changes Jan 30 (Reuters) - Amgen Inc AMGN.O : AMGEN - RECENTLY ANNOUNCED ORGANIZATIONAL CHANGES, MAINLY IN COMMERCIAL TEAM, THAT HAVE LED TO DISPLACEMENT OF ABOUT 300 TEAM MEMBERS BASED IN U.S. Further company coverage: AMGN.O
A



細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明